Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Phenylketonuria (PKU) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Phenylketonuria (PKU) - Pipeline Review, H1 2016', provides an overview of the Phenylketonuria (PKU) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Phenylketonuria (PKU) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) - The report reviews pipeline therapeutics for Phenylketonuria (PKU) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Phenylketonuria (PKU) therapeutics and enlists all their major and minor projects - The report assesses Phenylketonuria (PKU) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Phenylketonuria (PKU) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Phenylketonuria (PKU) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Phenylketonuria (PKU) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Phenylketonuria (PKU) Overview 6 Therapeutics Development 7 Pipeline Products for Phenylketonuria (PKU) - Overview 7 Phenylketonuria (PKU) - Therapeutics under Development by Companies 8 Phenylketonuria (PKU) - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Phenylketonuria (PKU) - Products under Development by Companies 11 Phenylketonuria (PKU) - Companies Involved in Therapeutics Development 12 BioMarin Pharmaceutical Inc. 12 Codexis, Inc. 13 Erytech Pharma SA 14 SOM Innovation Biotech SL 15 Synthetic Biologics, Inc. 16 Phenylketonuria (PKU) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 pegvaliase - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Recombinant Enzyme for Phenylketonuria - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Recombinant Phenylalanine-4-Hydroxylase Replacement for Phenylketonuria - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Recombinant Phenylalanine-4-Hydroxylase Replacement for Phenylketonuria - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 SOM-7400 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 SYN-200 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 SYNB-2010 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Phenylketonuria (PKU) - Recent Pipeline Updates 34 Phenylketonuria (PKU) - Dormant Projects 35 Phenylketonuria (PKU) - Product Development Milestones 36 Featured News & Press Releases 36 Jun 05, 2013: BioMarin Initiates Phase III Trial For PEG-PAL For Treatment Of Phenylketonuria 36 Sep 26, 2012: BioMarin Pharma to Initiate Phase III Program For PEG-PAL In Second Quarter Of 2013 36 Aug 02, 2010: BioMarin Reports Encouraging Preliminary Safety And Efficacy Trends In Phase II Clinical Study Of PEG-PAL In Phenylketonuria 38 Sep 22, 2009: BioMarin Initiates Phase II Clinical Study Of PEG-PAL In PKU 39 Jun 09, 2009: Results From Phase 1 Clinical Study Of PEG-PAL In PKU And Update On Phase 2 Clinical Study 39 May 20, 2008: BioMarin Initiates Phase 1 Clinical Study Of PEG-PAL In PKU 40 Nov 27, 2007: BioMarin Files Investigational New Drug Application For PEG-PAL For The Treatment Of PKU 40 May 16, 2005: BioMarin And Serono Form Strategic Alliance For The Development And Commercialization Of Phenoptin And Phenylase 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Phenylketonuria (PKU), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Phenylketonuria (PKU) - Pipeline by BioMarin Pharmaceutical Inc., H1 2016 12 Phenylketonuria (PKU) - Pipeline by Codexis, Inc., H1 2016 13 Phenylketonuria (PKU) - Pipeline by Erytech Pharma SA, H1 2016 14 Phenylketonuria (PKU) - Pipeline by SOM Innovation Biotech SL, H1 2016 15 Phenylketonuria (PKU) - Pipeline by Synthetic Biologics, Inc., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 Phenylketonuria (PKU) Therapeutics - Recent Pipeline Updates, H1 2016 34 Phenylketonuria (PKU) - Dormant Projects, H1 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.